Xu Y - Search Results

1

Hyperuricemia induces lipid disturbances mediated by LPCAT3 upregulation in the liver.

Liu N, Sun Q, Xu H, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W. Liu N, et al. Among authors: xu h, xu y. FASEB J. 2020 Oct;34(10):13474-13493. doi: 10.1096/fj.202000950R. Epub 2020 Aug 11. FASEB J. 2020. PMID: 32780898

2

Emerging technologies, recent developments, and novel applications for drug metabolite identification.

Lu W, Xu Y, Zhao Y, Cen X. Lu W, et al. Among authors: xu y. Curr Drug Metab. 2014;15(9):865-74. doi: 10.2174/1389200216666141230105649. Curr Drug Metab. 2014. PMID: 25537130 Review.

3

Uric Acid Produces an Inflammatory Response through Activation of NF-κB in the Hypothalamus: Implications for the Pathogenesis of Metabolic Disorders.

Lu W, Xu Y, Shao X, Gao F, Li Y, Hu J, Zuo Z, Shao X, Zhou L, Zhao Y, Cen X. Lu W, et al. Among authors: xu y. Sci Rep. 2015 Jul 16;5:12144. doi: 10.1038/srep12144. Sci Rep. 2015. PMID: 26179594 Free PMC article.

4

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities.

Xu Y, Lu W, Yang P, Peng W, Wang C, Li M, Li Y, Li G, Meng N, Lin H, Kan L, Wang S, Yang S, Yu L, Zhao Y. Xu Y, et al. BMC Cancer. 2015 Jul 18;15:525. doi: 10.1186/s12885-015-1451-2. BMC Cancer. 2015. PMID: 26187637 Free PMC article.

5

YL4073 is a potent autophagy-stimulating antitumor agent in an in vivo model of Lewis lung carcinoma.

Xu YZ, Li YH, Lu WJ, Lu K, Wang CT, Li Y, Lin HJ, Kan LX, Yang SY, Wang SY, Zhao YL. Xu YZ, et al. Oncol Rep. 2016 Apr;35(4):2081-8. doi: 10.3892/or.2016.4603. Epub 2016 Feb 1. Oncol Rep. 2016. PMID: 26847587

6

Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis.

Li ML, Xu YZ, Lu WJ, Li YH, Tan SS, Lin HJ, Wu TM, Li Y, Wang SY, Zhao YL. Li ML, et al. Among authors: xu yz. Oncol Lett. 2018 Mar;15(3):2839-2846. doi: 10.3892/ol.2017.7635. Epub 2017 Dec 19. Oncol Lett. 2018. PMID: 29435010 Free PMC article.

7

#2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models.

Lu WJ, Peng W, Sun QQ, Li YH, Chen B, Yu LT, Xu YZ, Wang SY, Zhao YL. Lu WJ, et al. Cell Death Discov. 2018 Feb 14;4:24. doi: 10.1038/s41420-018-0032-y. eCollection 2018 Dec. Cell Death Discov. 2018. PMID: 29531821 Free PMC article.

8

Novel agent #2714 potently inhibits lung cancer growth by suppressing cell proliferation and by inducing apoptosis in vitro and in vivo.

Lu W, Sun Q, Chen B, Li Y, Xu Y, Wang S. Lu W, et al. Among authors: xu y. Mol Med Rep. 2019 Jun;19(6):4788-4796. doi: 10.3892/mmr.2019.10114. Epub 2019 Apr 2. Mol Med Rep. 2019. PMID: 30942420 Free PMC article.

9

Activation of SREBP-1c alters lipogenesis and promotes tumor growth and metastasis in gastric cancer.

Sun Q, Yu X, Peng C, Liu N, Chen W, Xu H, Wei H, Fang K, Dong Z, Fu C, Xu Y, Lu W. Sun Q, et al. Among authors: xu h, xu y. Biomed Pharmacother. 2020 Aug;128:110274. doi: 10.1016/j.biopha.2020.110274. Epub 2020 May 25. Biomed Pharmacother. 2020. PMID: 32464305 Free article.

10

The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.

Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W. Liu N, et al. Among authors: xu h, xu y. Oxid Med Cell Longev. 2021 Mar 26;2021:1470380. doi: 10.1155/2021/1470380. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 33854690 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,025 results

Search Page

Filters